Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Appointed director
Inv. presentation
|
|
Sorrento Therapeutics, Inc. (SRNE)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/01/2016 |
8-K
| Resignation/termination of a director|
Docs:
|
"Sorrento Therapeutics Announces the Appointment of Dr. Yue Alexander Wu to its Board of Directors. SAN DIEGO, August 1, 2016 - Sorrento Therapeutics, Inc. , an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today the appointment of Yue Alexander Wu, Ph.D to its Board of Directors . Dr. Wu will also serve as a member of the Compensation Committee and Audit Committee of the Board. Doug Ebersole has resigned as a member of the Board for personal reasons. Dr. Wu is co-founder, President, Chief Executive Officer and Chief Scientific Officer of Crown Bioscience International, a leading global drug discovery and development solutions company, which he co-founded in 2006. From 2004 to 2006, Dr. Wu was Chief B..." |
|
| 05/01/2015 |
8-K
| Resignation/termination of a director |
| 08/21/2014 |
8-K
| Resignation/termination of a director |
| 08/08/2014 |
8-K
| Resignation/termination of a director, Appointed a new director|
Docs:
|
"Sorrento Therapeutics Appoints Douglas Ebersole to its Board of Directors San Diego, CA - August 8, 2014 - Sorrento Therapeutics, Inc. , a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced the addition of industry veteran Douglas Ebersole to its Board of Directors. Mr. Ebersole has over 25 years of broad business experience in industry as well as from consulting in a number of advisory roles, including as a former partner in a Silicon Valley law firm. Currently, Mr. Ebersole is an independent consultant and has worked primarily with PDL BioPharma since 2005. From 1992 to 2005, Mr. Ebersole served in various senior executive roles at PDL, including Senior Vice President - Corporate Development and Legal. During 2002, Mr. Ebers..." |
|
| 03/11/2014 |
8-K
| Resignation/termination of a director, Appointed a new director |
| 02/03/2014 |
8-K
| Resignation/termination of a director, Appointed a new director|
Docs:
|
"Sorrento Therapeutics Welcomes Daniel Levitt as a Director to its Board San Diego, CA - February 3, 2014 - Sorrento Therapeutics, Inc. a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the addition of Clinical Oncologist Daniel Levitt, M.D., Ph.D., as a member to its Board of Directors. He currently serves as Executive Vice President and Chief Medical Officer of CytRx Corporation. “Daniel's proven expertise overseeing the successful development of major oncology drugs will be invaluable to Sorrento as we advance our pipeline to address the unmet needs of cancer patients,” said Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento. Dr. Levitt commented, “I am excited to join Sorrento's Board of Directors at this piv..." |
|
| 01/09/2014 |
8-K
| Resignation/termination of a director|
Docs:
|
"Sorrento Therapeutics Appoints Amar Singh as Executive Vice President and Chief Business Officer SAN DIEGO, Jan. 8, 2014 /PRNewswire/ - Sorrento Therapeutics, Inc. , a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the appointment of Amar Singh as Executive Vice President and Chief Business Officer. In this role, Mr. Singh will be responsible for overseeing Sorrento's partnering activities. He brings over 25 years of experience in business and commercial development, strategic planning and operations to Sorrento. “Amar joins us at a pivotal phase in our Company's growth as we advance Cynviloq™ into its registrational trial and continue the development of resiniferatoxin ,” said Henry Ji, Ph.D., President and CEO of Sorrento. “...",
"Sorrento Therapeutics Welcomes William S. Marth as Chairman of the Board of Directors San Diego, CA - January 9, 2014 - Sorrento Therapeutics, Inc. a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the addition of industry veteran William Marth, as Chairman of the Board of Directors. Mr. Marth was the President and CEO of Teva - Americas until the end of 2012, and served as a senior advisor to Teva Pharmaceuticals until the end of 2013. During his tenure at Teva - Americas, Mr. Marth played a key role in building the organization to a $12 billion business and in the strategy behind the acquisitions of Cephalon for $6.8 billion and Barr Pharmaceuticals for $7.4 billion. Earlier in his career, he held leadership positions in sale..." |
|
|
|